TGFBR2 and neoplasm: The number of metastatic lung nodules was significantly decreased in mice that received miR-130a-, miR-145- and shRNA-TβRII-engineered HS/PCs compared to the control group (Fig. 2e), with no difference in primary tumor size (Supplementary Fig. 2i).